Search for: "v. Teva Pharmaceuticals USA, Inc." Results 101 - 120 of 440
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
23 Jul 2018, 12:05 pm by Dennis Crouch
Teva Pharmaceuticals USA, Inc., et al., No. 17-1229. [read post]
22 Jul 2018, 8:32 pm by Patent Docs
IPR2016-01127, IPR2016-01128, IPR2016-01129, IPR2016-01130, IPR2016-01131, and IPR2016-01132 (and parallel IPRs filed by Petitioners Teva Pharmaceuticals USA, Inc. and Akorn, Inc., which had... [read post]
18 Jul 2018, 11:23 am by Tryn T. Stimart and Jean E. Dassie
Teva Pharmaceuticals USA, Inc., a case with broad implications for the pharmaceutical industry. [read post]
13 Jul 2018, 5:48 pm by Lawrence B. Ebert
Teva Pharmaceuticals USA, Inc., is apertinent intervening case, but did not explain how it isan intervening change in law to the inherency doctrine,especially given that it is an on-sale bar case. 855 F.3d1356 (Fed. [read post]
25 Jun 2018, 7:03 am by Dennis Crouch
Teva Pharmaceuticals USA Inc., Docket No. 17-1229. [read post]
21 Jun 2018, 4:00 pm by Aurora Barnes
Teva Pharmaceuticals USA Inc. 17-1229 Issue: Whether, under the Leahy-Smith America Invents Act, an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art for purposes of determining the patentability of the invention. [read post]
20 Jun 2018, 5:00 pm by John Elwood
Teva Pharmaceuticals USA Inc., 17-1229, the bar section will be completely full on the day it is argued. [read post]
18 Jun 2018, 9:15 am by Dennis Crouch
Teva Pharmaceuticals USA, Inc., et al., No. 17-1229 (Supreme Court 2018), the petitioner has asked the Supreme Court to offer its statement on whether Congress altered the “on sale bar” to now apply only to non-confidential sales or offers. [read post]
7 Jun 2018, 4:59 pm by Patent Docs
Ltd.; Teva Pharmaceuticals International GMGH; and Teva Pharmaceuticals USA, Inc. [read post]
11 Apr 2018, 7:17 pm by Aurora Barnes
Teva Pharmaceuticals USA Inc. 17-1229 Issue: Whether, under the Leahy-Smith America Invents Act, an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art for purposes of determining the patentability of the invention. [read post]
21 Mar 2018, 1:34 pm by Pierre T. Nguyen
Une de ces unicités a récemment refait surface dans la décision du Federal Circuit dans Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc.: la mise en vente pouvant faire anticiper un dépôt de brevet américain. [read post]